ConductScience.org, home

Gene · 1457

CSNK2A1: casein kinase 2 alpha 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. CSNK2A1: casein kinase 2 alpha 1. Genes, record 1457. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1457

On this page

Gene

Symbol
CSNK2A1
HGNC
Name
casein kinase 2 alpha 1
HGNC
NCBI Gene ID
1457
NCBI Gene
HGNC ID
HGNC:2457
HGNC
Ensembl
ENSG00000101266
NCBI Gene
Aliases
CK2A1, CKII, Cka1, Cka2, OCNDS
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P68400Casein kinase II subunit alpha391321Ensembl, GeneID, HGNC

Source UniProt

Patents126

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4650780 A22025-11-19383P68400Espacenet
JP 2025517970 A2025-06-12383P68400Espacenet
JP 2025062604 A2025-04-1412122P68400Espacenet
JP 2025062604 A2025-04-1412123P68400Espacenet
EP 4480961 A12024-12-2594P68400Espacenet
EP 4433492 A12024-09-258P68400Espacenet
JP 2024123008 A2024-09-105291P68400Espacenet
JP 2024123008 A2024-09-105292P68400Espacenet
EP 4403581 A12024-07-242P68400Espacenet
JP 2024527193 A2024-07-2240P68400Espacenet

1 to 10 of 126

See all 126 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
SILMITASERTIBCHEMBL1230165Casein kinase II alpha inhibitorINHIBITOR

Source ChEMBL

Trials6

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT04668209SILMITASERTIBPHASE22023-08-14ClinicalTrials.gov
NCT04663737SILMITASERTIBPHASE22024-12-16ClinicalTrials.gov
NCT03897036SILMITASERTIBPHASE12025-05-20ClinicalTrials.gov
NCT02128282SILMITASERTIBPHASE1/PHASE2ClinicalTrials.gov
NCT01199718SILMITASERTIBPHASE1ClinicalTrials.gov
NCT00891280SILMITASERTIBPHASE1ClinicalTrials.gov

NIH grants2,181

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleCSNK2A1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant152025
P30CA008748Cancer Center Support Grant72025
P01CA013106Targeting Transcription and Splicing in Cancer62025
P01CA092584Structural Cell Biology of DNA Repair Machines52025
R01AG011085Ubiquitin‐mediated proteolysis and cell cycle control52025
ZIASC010357Gene Expression and Post-Transcriptional Regulation of DNA Tumor Viruses52025
P30CA013330Cancer Center Support Grant42025
P30CA015083Mayo Clinic Comprehensive Cancer Center Support Grant42025
P30CA030199Cancer Center Support Grant (CCSG)42025
P30CA046934University of Colorado Cancer Center Support Grant42025

1 to 10 of 2,181Source NIH's project files

See all 2,181 nih grants

Papers3,014

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Phosphorylation destabilizes Per3 to promote gallbladder carcinoma.Exp Cell Res202642777803PubTator, text miningPubMed
Phosphorylated HPV‑16 E7 disrupts planar cell polarity in cervical cancer cells through vangl1 dysregulation.PLoS Pathog202642766580PubTator, text miningPubMed
Broadening the Okur-Chung syndrome phenotype: adult-onset metabolic features and a contiguous 20p13 deletion in a Turkish multicenter cohort.J Hum Genet202642706398PubTator, text miningPubMed
Correction to "A Case of CSNK2A1 Gene Variant Causing Okur-Chung Syndrome and Analysis of the Clinical Phenotypic Spectrum".Mol Genet Genomic Med202642587398PubTator, text miningPubMed
A Temporal Phospho-acetylome Atlas of Human Myogenesis Identifies coordinated Post-Translational Regulation.Mol Cell Proteomics202642392363PubTator, text miningPubMed
Sleep profiles in individuals with rare neurogenetic syndromes.Dev Med Child Neurol202642338150PubTator, text miningPubMed
Systems-level multi-omics dissection of syndromic and idiopathic autism reveals distinct regulatory architectures, candidate molecular signatures, and potential therapeutic targets.Comput Biol Med202642330854PubTator, text miningPubMed
Establishment and validation of a novel anoikis-related prognostic signature of lung squamous cell carcinoma.Transl Cancer Res202642180924PubTator, text miningPubMed
Subtype-Independent Activation of NF-κB Signaling in Breast Cancer.Int J Mol Sci202642123635PubTator, text miningPubMed
Evaluating splicing factor and kinase network crosstalk through global phosphoproteomics.bioRxiv202642079238PubTator, text miningPubMed

1 to 10 of 3,014

See all 3,014 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/1457

GET https://conductscience.org/api/genes/v1/1457/patents?page=2